These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35987276)

  • 1. Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".
    Choi J
    J Hepatol; 2022 Nov; 77(5):1472-1474. PubMed ID: 35987276
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.
    Liu SY; Yuan C; Tong XM
    J Hepatol; 2022 Nov; 77(5):1471-1472. PubMed ID: 35863489
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    Yoo S; Kim JY; Lim YS; Han S; Choi J
    J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.
    Tang Y; Chen Y; Chen HN
    J Hepatol; 2022 Dec; 77(6):1722-1724. PubMed ID: 35690263
    [No Abstract]   [Full Text] [Related]  

  • 5. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of chronic hepatitis B virus DNA negative transformation and HBsAg clearance on the occurrence of hepatocellular carcinoma].
    Zhou JL; Wang BQ; Shi YW; You H
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):831-833. PubMed ID: 31941236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma.
    Chen YC; Liaw YF
    Aliment Pharmacol Ther; 2016 Jul; 44(2):210-1. PubMed ID: 27296691
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Jiang JF; Sun J; Shi J; Liu X
    Aliment Pharmacol Ther; 2017 May; 45(9):1286-1288. PubMed ID: 28370051
    [No Abstract]   [Full Text] [Related]  

  • 11. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
    Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
    Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
    Anderson RT; Choi HSJ; Lenz O; Peters MG; Janssen HLA; Mishra P; Donaldson E; Westman G; Buchholz S; Miller V; Hansen BE
    Clin Gastroenterol Hepatol; 2021 Mar; 19(3):463-472. PubMed ID: 32473348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR
    Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection.
    Schemmer P; Burra P; Hu RH; Hüber CM; Loinaz C; Machida K; Vogel A; Samuel D
    Liver Int; 2022 Feb; 42(2):288-298. PubMed ID: 34846790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma.
    Kubo S; Hirohashi K; Tanaka H; Tsukamoto T; Shuto T; Higaki I; Takemura S; Yamamoto T; Nishiguchi S; Kinoshita H
    Dig Surg; 2001; 18(1):26-33. PubMed ID: 11244256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma.
    Sohn W; Paik YH; Kim JM; Kwon CH; Joh JW; Cho JY; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Ann Surg Oncol; 2014 Jul; 21(7):2429-35. PubMed ID: 24619495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.